Laser capture microdissection and protein microarray analysis of human non-small cell lung cancer: Differential epidermal growth factor receptor (EGPR) phosphorylation events associated with mutated EGFR compared with wild type

Amy J. VanMeter, Adrianna S. Rodriguez, Elise D. Bowman, Jin Jen, Curtis C. Harris, Jianghong Deng, Valerie S. Calvert, Alessandra Silvestri, Claudia Fredolini, Vikas Chandhoke, Emanuel F. Petricoin, Lance A. Liotta, Virginia Espina

Research output: Contribution to journalArticlepeer-review

Abstract

Little is known about lung carcinoma epidermal growth factor (EGF) kinase pathway signaling within the context of the tissue microenvironment. We quantitatively profiled the phosphorylation and abundance of signal pathway proteins relevant to the EGF receptor within laser capture microdissected untreated, human non-small cell lung cancer (NSCLC) (n = 25) of known epidermal growth factor receptor (EGFR) tyrosine kinase domain mutation status. We measured six phosphorylation sites on EGFR to evaluate whether EGFR mutation status in vivo was associated with the coordinated phosphorylation of specific multiple phosphorylation sites on the EGFR and down-stream proteins. Reverse phase protein array quantitation of NSCLC revealed simultaneous increased phosphorylation of EGFR residues Tyr-1148 (p <0.044) and Tyr-1068 (p <0.026) and decreased phosphorylation of EGFR Tyr-1045 (p <0.002), HER2 Tyr-1248 (p <0.015), IRS-1 Ser-612 (p <0.001), and SMAD Ser-465/467 (p <0.011) across all classes of mutated EGFR patient samples compared with wild type. To explore which subset of correlations was influenced by ligand induction versus an intrinsic phenotype of the EGFR mutants, we profiled the time course of 115 cellular signal proteins for EGF ligand-stimulated (three dosages) NSCLC mutant and wild type cultured cell lines. EGFR mutant cell lines (H1975 L858R) displayed a pattern of EGFR Tyr-1045 and HER2 Tyr-1248 phosphorylation similar to that found in tissue. Persistence of phosphorylation for AKT Ser-473 following ligand stimulation was found for the mutant. These data suggest that a higher proportion of the EGFR mutant carcinoma cells may exhibit activation of the phosphatidylinositol 3-kinase/protein kinase B (AKT)/mammalian target of rapamycin (MTOR) pathway through Tyr-1148 and Tyr-1068 and suppression of IRS-1 Ser-612, altered heterodimerization with ERBB2, reduced response to transforming growth factor β suppression, and reduced ubiquidnation/degradation of the EGFR through EGFR Tyr-1045, thus providing a survival advantage. This is the first comparison of multiple, site-specific phosphoproteins with the EGFR tyrosine kinase domain mutation status in vivo.

Original languageEnglish (US)
Pages (from-to)1902-1924
Number of pages23
JournalMolecular and Cellular Proteomics
Volume7
Issue number10
DOIs
StatePublished - Oct 2008
Externally publishedYes

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Analytical Chemistry

Fingerprint Dive into the research topics of 'Laser capture microdissection and protein microarray analysis of human non-small cell lung cancer: Differential epidermal growth factor receptor (EGPR) phosphorylation events associated with mutated EGFR compared with wild type'. Together they form a unique fingerprint.

Cite this